Treatment for HBV-MN Patients in Chinese: An Open Parallel Controlled Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01152060

Recruitment Status : Unknown

Verified May 2010 by Nanchang University.
Recruitment status was: Active, not recruiting

First Posted : June 29, 2010

Last Update Posted : June 29, 2010

Sponsor:

Information provided by:

Nanchang University

Study Description

Brief Summary:

Lamivudine treatment for HBV-DNA negative HBV-GN patients.

Condition or disease
Proteinuria HBVe-antigen

Detailed Description:

lamivudine and predinisone treatment for HBV-DNA negative HBV-GN patients.

Study Design

Layout table for study information

Study Type :	Observational
Estimated Enrollment :	10 participants
Observational Model:	Cohort
Time Perspective:	Prospective
Official Title:	an Open Parallel Clinical Trial in HBV-GN Patients
Study Start Date :	January 2010
Estimated Primary Completion Date :	November 2010
Estimated Study Completion Date :	November 2010

Groups and Cohorts

Group/Cohort
prednisone
prednisone and anti-virus

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 60 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

HBV-MN patients with heavy proteinuria in adults; HBsAg or HBeAg positive; HBV-DNA negative

Criteria

Inclusion Criteria:

Adult HBV-GN patients with biopsy-proven MN, heavy protinuria, HBsAg or HBeAg positive, HBV-DNA negative

Exclusion Criteria:

Primary MN patients, HBV-DNA positive

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01152060

Sponsors and Collaborators

Nanchang University

Investigators

Layout table for investigator information

Study Director:	Gaosi XU, MD & PhD	second affiliated hospital to nanchang university

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

von Groote TC, Williams G, Au EH, Chen Y, Mathew AT, Hodson EM, Tunnicliffe DJ. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2021 Nov 15;11:CD004293. doi: 10.1002/14651858.CD004293.pub4. Review.

Xu G, Duang Z, Wu X, Zou H, Fang X, Tu W. Treatment of hepatitis B virus-associated membranous nephritis patients in Chinese: an open parallel controlled trial. Clin Chem Lab Med. 2011 Jun;49(6):1077-8. doi: 10.1515/CCLM.2011.168. Epub 2011 Mar 17.

Layout table for additonal information

Responsible Party:	ethics committee of Nanchang University, second affiliated hospital
ClinicalTrials.gov Identifier:	NCT01152060
First Posted:	June 29, 2010 Key Record Dates
Last Update Posted:	June 29, 2010
Last Verified:	May 2010

Keywords provided by Nanchang University:


remission of proteinuria HBVe-antigen

Additional relevant MeSH terms:

Layout table for MeSH terms

Proteinuria Urination Disorders Urologic Diseases Urological Manifestations

To Top